The U.S. Food and Drug Administration approved a new indication for GlaxoSmithKline plc and Innoviva Inc.’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to the product’s current license for use in patients with chronic obstructive pulmonary disease (COPD).
Gilead Sciences Inc. expects supply of the potential COVID-19 drug remdesivir to exceed two million courses by year-end, more than double the company’s previous target of 1 million.
Gilead Sciences Inc is developing easier-to-administer versions of the company’s antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals.
Unlisted Covis Pharma B.V. started a late-stage U.S. randomized trial of the company’s asthma drug Alvesco in non-hospitalized patients with symptomatic COVID-19, hoping the inhaled drug treats symptoms and limits viral replication.
Swiss pharma giant Novartis is writing off the company’s program to develop a generic copy of GlaxoSmithKline’s blockbuster inhaler Advair.
AstraZeneca announced a bold plan to have zero carbon emissions from the company’s global operations within the next five years.
A British court ruled in favor of Vectura Group and the company’s partner Sandoz over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.
GlaxoSmithKline Plc said the company’s three-in-one drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to the British drugmaker’s lung medicines division.
GlaxoSmithKline plc and Innoviva Inc. announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease. This is the first regulatory filing to be made in Japan for a triple COPD therapy in a single inhaler.
Teva Pharmaceutical Industries Ltd. announced FDA approval of two products for adolescent and adult patients with asthma: AirDuo RespiClick and ArmonAir RespiClick.
